J Michael Dixon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6024370/publications.pdf

Version: 2024-02-01

92 papers	4,463 citations	186265 28 h-index	102487 66 g-index
92 all docs	92 docs citations	92 times ranked	4823 citing authors

#	Article	IF	Citations
1	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2022, 28, 3618-3629.	7.0	12
2	Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncology, 2021, 17, 1665-1681.	2.4	26
3	The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer. Journal of Personalized Medicine, 2021, 11, 618.	2.5	11
4	Diagnostic accuracy of core biopsy in patients presenting with axillary lymphadenopathy and suspected non-breast malignancy. European Journal of Surgical Oncology, 2021, 47, 1575-1580.	1.0	1
5	A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer. Journal of Personalized Medicine, 2021, 11, 796.	2.5	7
6	Postmastectomy radiotherapy for all node positive patients: The case against. European Journal of Surgical Oncology, 2021, 47, 2515-2520.	1.0	1
7	The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. Journal of Personalized Medicine, 2021, 11, 1073.	2.5	7
8	Twentyâ€five years of change in the management of the axilla in breast cancer. Breast Journal, 2020, 26, 22-26.	1.0	12
9	Was it the saline or the silicone gel that turned green in a Becker expander implant reconstruction over time?. Breast Journal, 2020, 26, 2235-2236.	1.0	1
10	Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer. Breast Cancer Research and Treatment, 2020, 184, 335-343.	2.5	7
11	No evidence of benefit for laminar flow in theatre for sling-assisted, implant-based breast reconstruction. Journal of the Royal College of Surgeons of Edinburgh, 2020, 19, e112-e116.	1.8	1
12	Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. Molecular Cancer Therapeutics, 2020, 19, 680-689.	4.1	44
13	Evidence-based guidelines for managing patients with primary ER+ HER2â˜ breast cancer deferred from surgery due to the COVID-19 pandemic. Npj Breast Cancer, 2020, 6, 21.	5.2	42
14	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2â˜ Primary Breast Cancer. Clinical Cancer Research, 2020, 26, 4242-4249.	7.0	29
15	Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches. BMC Bioinformatics, 2020, 21, 30.	2.6	32
16	Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3670-3678.	3.6	23
17	Oncoplastic breast conservation occupies a niche between standard breast conservation and mastectomy â€“ A population-based prospective audit in Scotland. European Journal of Surgical Oncology, 2019, 45, 1806-1811.	1.0	8
18	Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. Breast Cancer Research, 2019, 21, 2.	5.0	29

#	Article	IF	Citations
19	The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Review of Anticancer Therapy, 2019, 19, 121-138.	2.4	11
20	A population-based audit of surgical practice and outcomes of oncoplastic breast conservations in Scotland â€“ An analysis of 589 patients. European Journal of Surgical Oncology, 2018, 44, 939-944.	1.0	21
21	Evidence-based advice for patients following axillary surgery. Breast Cancer Management, 2018, 7, BMT15.	0.2	3
22	Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy. Gland Surgery, 2018, 7, 520-524.	1.1	10
23	Breast implants and anaplastic large cell lymphoma. BMJ: British Medical Journal, 2018, 363, k5054.	2.3	11
24	Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology, The, 2018, 19, 1516-1529.	10.7	52
25	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 228-235.	2.5	6
26	Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. Cancer Treatment Reviews, 2017, 55, 163-172.	7.7	29
27	Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ. European Journal of Surgical Oncology, 2017, 43, 2029-2035.	1.0	9
28	Excision margins in breast conserving therapy. Breast Cancer Management, 2017, 6, 97-99.	0.2	0
29	Pre-operative Endocrine Therapy. Current Breast Cancer Reports, 2017, 9, 202-209.	1.0	17
30	A Rare Presentation of Chest Wall Chondrosarcoma as a Breast Mass. Breast Journal, 2016, 22, 235-237.	1.0	1
31	Update from the 33rd Miami Breast Cancer Conference, FL, USA, 10â€“13 March 2016. Breast Cancer Management, 2016, 5, 47-51.	0.2	0
32	Importance of margin width in breastâ€conserving treatment of early breast cancer. Journal of Surgical Oncology, 2016, 113, 609-615.	1.7	29
33	Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Research, 2016, 18, 118.	5.0	65
34	Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies. Scientific Reports, 2016, 6, 29434.	3.3	13
35	Contemporary social media engagement by breast surgeons. Breast, 2016, 30, 172-174.	2.2	5
36	Sentinel Lymph Node Biopsy in Breast Cancer Surgery. Annals of Surgical Oncology, 2016, 23, 3426-3428.	1.5	2

#	Article	IF	Citations
37	Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery. Breast Cancer Research and Treatment, 2016, 160, 387-391.	2.5	26
38	Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series ofin vitrobreast cancer models. Oncotarget, 2015, 6, 24856-24870.	1.8	76
39	Authors' reply to Rayter. BMJ, The, 2015, 350, h714-h714.	6.0	0
40	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Modern Pathology, 2015, 28, 1185-1201.	5.5	205
41	Endocrine resistance in breast cancer â€“ An overview and update. Molecular and Cellular Endocrinology, 2015, 418, 220-234.	3.2	280
42	Role of endocrine therapy in ER⁺/HER2⁺breast cancers. Breast Cancer Management, 2014, 3, 103-111.	0.2	2
43	Intraoperative assessment of axillary lymph nodes in patients with breast cancer. BMJ, The, 2014, 349, g6803-g6803.	6.0	9
44	Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research, 2014, 74, 5371-5376.	0.9	34
45	In Regard to Moran etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1139.	0.8	5
46	Reply to S. Pauwels et al. Journal of Clinical Oncology, 2013, 31, 509-510.	1.6	1
47	Conference Scene: 8th European Breast Cancer Conference, Vienna 2012. Breast Cancer Management, 2012, 1, 119-121.	0.2	0
48	Adapting to change and seeing the opportunities in breast cancer management. Breast Cancer Management, 2012, 1, 1-3.	0.2	0
49	Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer. Journal of Clinical Oncology, 2012, 30, 2977-2980.	1.6	104
50	Endocrine Therapy in DCIS: How Do We Proceed?. Breast Journal, 2012, 18, 295-298.	1.0	2
51	Preoperative Endocrine Therapy: Preferred Therapy for Whom?. Current Breast Cancer Reports, 2012, 4, 39-47.	1.0	3
52	Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget, 2012, 3, 608-619.	1.8	57
53	Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Research and Treatment, 2011, 125, 741-749.	2.5	17
54	Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Research and Treatment, 2011, 130, 871-877.	2.5	57

#	Article	IF	Citations
55	Treatment of breast infection. BMJ: British Medical Journal, 2011, 342, d396-d396.	2.3	47
56	A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2010, 119, 643-651.	2.5	31
57	So you want to be â€¦ a breast surgeon. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, M16-M16.	0.5	0
58	Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial. Clinical Cancer Research, 2010, 16, 1605-1612.	7.0	42
59	Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. European Journal of Cancer, 2010, 46, 3219-3232.	2.8	342
60	Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Research and Treatment, 2009, 113, 145-151.	2.5	89
61	Breast screening has increased the number of mastectomies. Breast Cancer Research, 2009, 11, S19.	5.0	12
62	Reducing early recurrence with adjuvant aromatase inhibitors: What is the evidence?. Breast, 2008, 17, 353-360.	2.2	4
63	Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for. Breast Cancer Research, 2008, 10, S7.	5.0	5
64	Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1671-1676.	1.6	156
65	Role of Erbb2 in Selection for Adjuvant Tamoxifen or Aromatase Inhibitors. Women's Health, 2008, 4, 229-231.	1.5	1
66	Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer. Expert Review of Anticancer Therapy, 2008, 8, 453-463.	2.4	10
67	Breast abscess. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 315-320.	0.5	9
68	Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 167-170.	6.3	608
69	For the use of ultrasound by surgeons. Breast Cancer Online: BCO, 2007, 10, 1-3.	0.1	3
70	DCIS and aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 173-179.	2.5	11
71	Neoadjuvant Use of Endocrine Therapy in Breast Cancer. Breast Journal, 2007, 13, 243-250.	1.0	18
72	Extended adjuvant therapy with letrozole: reducing the risk of recurrence. Expert Review of Anticancer Therapy, 2006, 6, 849-859.	2.4	3

#	Article	IF	Citations
73	Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies. Expert Opinion on Pharmacotherapy, 2006, 7, 2465-2479.	1.8	6
74	Neoadjuvant Use of Hormonal Therapy in Elderly Patients with Early or Locally Advanced Hormone Receptorâ€“Positive Breast Cancer. Oncologist, 2006, 11, 1081-1088.	3.7	37
75	Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer. Clinical Cancer Research, 2006, 12, 1024s-1030s.	7.0	105
76	Estrogen-Independent Proliferation Is Present in Estrogen-ReceptorHER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole. Journal of Clinical Oncology, 2006, 24, 3019-3025.	1.6	170
77	Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancerâ€”A Study from the IMPACT Trialists. Journal of Clinical Oncology, 2005, 23, 2477-2492.	1.6	263
78	Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial. Journal of Clinical Oncology, 2005, 23, 5108-5116.	1.6	693
79	Surgical issues surrounding use of aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 97-103.	2.5	6
80	Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clinical Cancer Research, 2005, 11, 951s-8s.	7.0	195
81	Breast cancer (non-metastatic). Clinical Evidence, 2005, , 2226-57.	0.2	0
82	Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 307-316.	1.8	15
83	Role of endocrine therapy in the neoadjuvant surgical setting. Annals of Surgical Oncology, 2004, 11, 18S-23S.	1.5	11
84	The scientific value of preoperative studies and how they can be used. Breast Cancer Research and Treatment, 2004, 87, 19-26.	2.5	28
85	Breast cancer (non-metastatic). Clinical Evidence, 2004, , 2300-33.	0.2	0
86	Breast cancer (non-metastatic). Clinical Evidence, 2003, , 1940-70.	0.2	0
87	Endocrine and Clinical Endpoints of Exemestane as Neoadjuvant Therapy. Cancer Control, 2002, 9, 9-15.	1.8	59
88	Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. Expert Review of Anticancer Therapy, 2002, 2, 267-275.	2.4	23
89	Hormone replacement therapy: is it safe for breast cancer patients?. Medical Journal of Australia, 2002, 177, 340-341.	1.7	3
90	One stop clinics should not be abandoned. BMJ, The, 2002, 324, 507.	6.0	2

#	Article	IF	Citations
91	Breast cancer: non-metastatic. Clinical Evidence, 2002, , 1603-30.	0.2	0
92	Breast cancer: non-metastatic. Clinical Evidence, 2002, , 1811-39.	0.2	1